BioFire’s Covid Test Panel Receives FDA Marketing Authorization

FDA granted marketing authorization to BioFire’s Respiratory Panel 2.1 (RP2.1), a Covid-19 diagnostic test.

• The test is able to simultaneously detect and identify multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs
• The diagnostic test already had an Emergency Use Authorization
• Product is the first SARS-CoV-2 diagnostic test that will be permitted to be marketed beyond the public health emergency

To view the source of this information click here

To contact the reporter on this story:
Linly Lin in San Francisco at llin153@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2021 Bloomberg L.P. ...